Brand Name

Thiothixene

View Brand Information
FDA approval date: April 05, 2019
Classification: Typical Antipsychotic
Form: Capsule

What is Thiothixene?

Thiothixene capsules are effective in the management of schizophrenia. Thiothixene capsules have not been evaluated in the management of behavioral complications in patients with mental retardation.

Approved To Treat

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Considerations for Augmenting Aripiprazole Long-Acting Injectables with Other Antipsychotics: A Mini-Review.
Considerations for Augmenting Aripiprazole Long-Acting Injectables with Other Antipsychotics: A Mini-Review.
Journal: Diseases (Basel, Switzerland)
Published: July 18, 2025
Treatment of schizotypal disorder: A systematic review and GRADE evaluation of the certainty of evidence.
Treatment of schizotypal disorder: A systematic review and GRADE evaluation of the certainty of evidence.
Journal: Schizophrenia research
Published: June 24, 2025
The antipsychotic drug thiothixene stimulates macrophages to clear pathogenic cells by inducing arginase 1 and continual efferocytosis.
The antipsychotic drug thiothixene stimulates macrophages to clear pathogenic cells by inducing arginase 1 and continual efferocytosis.
Journal: Science signaling
Published: April 08, 2025
View All Latest Advances